Medicare AdvantageCoverageMedium impact
MA08.125c, Lurbinectedin (Zepzelca®)
Independence Blue Cross·Oncology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.125c for Lurbinectedin (Zepzelca®) has been reissued with an effective date of May 28, 2025. This is a pharmacy policy update that may affect coverage or billing requirements for this oncology medication.
Action Required
Before May 28, 2025: Billing team should review the full policy details at the source URL to understand specific changes to Lurbinectedin coverage requirements. Update billing procedures and prior authorization workflows as needed for Medicare Advantage patients receiving this oncology medication.